Literature DB >> 23525828

Serum sclerostin levels in healthy men over 50 years of age.

Harjit Pal Bhattoa1, John Wamwaki, Edit Kalina, Roza Foldesi, Adam Balogh, Peter Antal-Szalmas.   

Abstract

The aim of this study is to evaluate the relationship of serum sclerostin levels with age, cystatin C, bone mineral density (BMD) and biochemical markers of bone turnover in healthy Hungarian men >50 years of age. We determined serum levels of sclerostin and examined its relationship to age, cystatin C, osteocalcin, C-terminal telopeptides of type-I collagen, procollagen type 1 amino-terminal propeptide, 25-hydroxyvitamin D, parathyroid hormone, and L1-L4 (LS) and femur neck (FN) BMD data available from 194 randomly selected ambulatory men belonging to the HunMen cohort. In the study population as a whole [n = 194; age (median, range) 59 (51-81) years], statistically significant correlation was found between sclerostin and age (r = 0.211; p = 0.003), cystatin C (r = 0.246; p = 0.001), FN BMD (r = 0.147; p = 0.041) and LS BMD (r = 0.169; p = 0.019). Compared to middle-aged men (age ≤59 years, n = 98), elderly men (age >59 years, n = 96) had significantly higher serum sclerostin levels (67.8 ± 15.9 vs 63.5 ± 14 pmol/L; p = 0.047). Among men with normal (T score >-1.0) FN BMD, the elderly had significantly higher serum sclerostin levels compared to the middle-aged men (70.4 ± 17 vs 63.9 ± 11.5 pmol/L; p = 0.019). Furthermore, among the elderly men cystatin C was the only significant predictor of serum sclerostin levels (standardized regression coefficient (β) = 0.487; p < 0.001). In the studied healthy elderly cohort, this study reports a significant increase in sclerostin levels with increasing age and deteriorating kidney function as determined by plasma cystatin C levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23525828     DOI: 10.1007/s00774-013-0451-z

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  21 in total

1.  Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women.

Authors:  Zhifeng Sheng; Dejun Tong; Yangna Ou; Hongbin Zhang; Zhimin Zhang; Shuang Li; Jianlin Zhou; Jian Zhang; Eryuan Liao
Journal:  Clin Endocrinol (Oxf)       Date:  2012-06       Impact factor: 3.478

Review 2.  Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study.

Authors:  H P Bhattoa; E Nagy; C More; J Kappelmayer; A Balogh; E Kalina; P Antal-Szalmas
Journal:  Osteoporos Int       Date:  2012-03-16       Impact factor: 4.507

3.  Sclerostin levels during growth in children.

Authors:  S Kirmani; S Amin; L K McCready; E J Atkinson; L Joseph Melton; R Müller; S Khosla
Journal:  Osteoporos Int       Date:  2011-05-27       Impact factor: 4.507

4.  The diagnosis of osteoporosis.

Authors:  J A Kanis; L J Melton; C Christiansen; C C Johnston; N Khaltaev
Journal:  J Bone Miner Res       Date:  1994-08       Impact factor: 6.741

5.  Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

Authors:  Faryal S Mirza; I Desmond Padhi; Lawrence G Raisz; Joseph A Lorenzo
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

Review 6.  Regulation of bone mass by Wnt signaling.

Authors:  Venkatesh Krishnan; Henry U Bryant; Ormond A Macdougald
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

7.  Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.

Authors:  S A Polyzos; A D Anastasilakis; C Bratengeier; W Woloszczuk; A Papatheodorou; E Terpos
Journal:  Osteoporos Int       Date:  2011-01-11       Impact factor: 4.507

8.  Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.

Authors:  Alexander G Robling; Paul J Niziolek; Lee A Baldridge; Keith W Condon; Matthew R Allen; Imranul Alam; Sara M Mantila; Jelica Gluhak-Heinrich; Teresita M Bellido; Stephen E Harris; Charles H Turner
Journal:  J Biol Chem       Date:  2007-12-17       Impact factor: 5.157

9.  Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.

Authors:  Ulrike I Mödder; Kelley A Hoey; Shreyasee Amin; Louise K McCready; Sara J Achenbach; B Lawrence Riggs; L Joseph Melton; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2011-02       Impact factor: 6.741

10.  Regulation of circulating sclerostin levels by sex steroids in women and in men.

Authors:  Ulrike Il Mödder; Jackie A Clowes; Kelley Hoey; James M Peterson; Louise McCready; Merry Jo Oursler; B Lawrence Riggs; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

View more
  13 in total

1.  Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.

Authors:  Masafumi Kashii; Yohei Matuso; Tsuyoshi Sugiura; Takahito Fujimori; Yukitaka Nagamoto; Takahiro Makino; Takashi Kaito; Kosuke Ebina; Motoki Iwasaki; Hideki Yoshikawa
Journal:  J Bone Miner Metab       Date:  2015-06-04       Impact factor: 2.626

Review 2.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

3.  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Jannis Kountouras; Polyzois Makras; Athanasios Papatheodorou; Panagiotis Kokkoris; Grigorios T Sakellariou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

4.  Serum sclerostin and DKK1 in relation to exercise against bone loss in experimental bed rest.

Authors:  Daniel L Belavý; Natalie Baecker; Gabriele Armbrecht; Gisela Beller; Judith Buehlmeier; Petra Frings-Meuthen; Jörn Rittweger; Heinz J Roth; Martina Heer; Dieter Felsenberg
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

5.  Musculoskeletal Biomarkers Response to Exercise in Older Adults.

Authors:  Eduardo L Abreu; Amy Vance; An-Lin Cheng; Marco Brotto
Journal:  Front Aging       Date:  2022-07-04

6.  Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; MaryAnn O'Riordan; Corrilynn O Hileman; Eric Rapaport; Danielle Labbato; Thomas B Campbell; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-27       Impact factor: 2.205

7.  Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice.

Authors:  Michelle L Thompson; Juan Miguel Jimenez-Andrade; Patrick W Mantyh
Journal:  J Histochem Cytochem       Date:  2015-12-23       Impact factor: 2.479

8.  Exercise does not enhance aged bone's impaired response to artificial loading in C57Bl/6 mice.

Authors:  Lee B Meakin; Chinedu Udeh; Gabriel L Galea; Lance E Lanyon; Joanna S Price
Journal:  Bone       Date:  2015-07-02       Impact factor: 4.398

9.  Sost deficiency led to a greater cortical bone formation response to mechanical loading and altered gene expression.

Authors:  David Pflanz; Annette I Birkhold; Laia Albiol; Tobias Thiele; Catherine Julien; Anne Seliger; Erin Thomson; Ina Kramer; Michaela Kneissel; Georg N Duda; Uwe Kornak; Sara Checa; Bettina M Willie
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

Review 10.  Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics.

Authors:  Abhishek Chandra; Jyotika Rajawat
Journal:  Int J Mol Sci       Date:  2021-03-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.